Radiotheranostics Resources
Explore the science behind Radiotheranostics!
From nuclear medicine and radionuclides to therapeutic applications and expert insights, access trusted resources to better understand this innovative approach to cancer care.
What is Nuclear medicine?
Natural Radioactivity first appeared concomitantly to the creation of the Earth, and the radionuclides that can still be found in soil today are in fact long period Isotopes or Decay nuclides dating from original matter. As a consequence, man has always been exposed to environmental Radioactivity, whether from terrestrial or cosmic origin, and of course we continue to find these radionuclides in our food and indirectly in each of our body cells.
A Radionuclide is a substance that degrades in a very constant manner over time and emits one or several radiations. This degradation or Decay is defined by a constant, the period (or Half-life) corresponding to the time it takes for half of the remaining substance to disappear. This Half-life is specific for each Radionuclide.
The type of emitted Radiation is also specific for each Radionuclide.
There are five types of Radiation which are of interest to Nuclear medicine:
- for diagnosis purposes, Gamma rays (γ) and beta plus (or Positron) emissions (β+) have led to the development of respectively
- the Imaging modalities SPECT (Single Photon Emission Computed Tomography)
- and PET (Positron Emission Tomography). Beta minus (β–), Alpha (α) radiations and soon conversion or Auger electrons are used in Metabolic Radiotherapy.
Among all the radionuclides with potential in Nuclear medicine, we shall remember those that are currently most widely used:
- Iodine-123 and Technetium-99m as γ emitters,
- Fluorine-18 and Gallium-68 as β+ emitters,
- Iodine-131 and Lutetium-177 as β– emitters.
- Newcomers will include Astatine-211 and Actinium-225 in the Alpha-emitting series
- and Tin-117m as Conversion electron emitter.
What are Radionuclides?
Natural Radioactivity first appeared concomitantly with the creation of the Earth, and the radionuclides that can still be found in soil today are in fact long-period Isotopes or Decay nuclides dating from the original matter. As a consequence, man has always been exposed to environmental Radioactivity, whether from terrestrial or cosmic origin, and of course, we continue to find these radionuclides in our food and indirectly in each of our body cells.
A Radionuclide is a substance that degrades in a very constant manner over time and emits one or several radiations. This degradation or Decay is defined by a constant, the period (or Half-life) corresponding to the time it takes for half of the remaining substance to disappear. This Half-life is specific for each Radionuclide.
Types of radionuclides?
The type of emitted Radiation is also specific for each Radionuclide. There are five types of Radiation which are of interest to Nuclear medicine: for diagnosis purposes, Gamma rays (γ) and beta plus (or Positron) emissions (β+) have led to the development of respectively the Imaging modalities SPECT (Single Photon Emission Computed Tomography) and PET (Positron Emission Tomography). Beta minus (β–), Alpha (α) radiations and soon conversion or Auger electrons are used in Metabolic Radiotherapy.
Among all the radionuclides with potential in Nuclear medicine, we shall remember those that are currently most widely used: Iodine-123 and Technetium-99m as γ emitters, Fluorine-18 and Gallium-68 as β+ emitters, Iodine-131 and Lutetium-177 as β– emitters. Newcomers will include Astatine-211 and Actinium-225 in the Alpha-emitting series and Tin-117m as Conversion electron emitter.
Radiotherapeutics
The list of radiotherapeutics below is intended to be as exhaustive as possible. Despite our best efforts to regularly update the information, the field of radiotherapeutics is changing and evolving rapidly. Should you notice any missing molecules or wish to add some elements of precision, please contact us. This information is public. However, if you wish to use it, please mention the Oncidium foundation in reference – A very special thanks to MEDraysintell for the scientific and technical support.
Last update July 2023.
Radiotherapeutic | Target Mechanism | Radionuclide | Ligand/Carrier | Indication | Status | Radiation Type |
---|---|---|---|---|---|---|
Ac-225-DOTA-SP | Substance P | 225Ac | Substance P | Glioblastoma | In Clinical development | alpha (α) |
Ac-225-DOTA-YS5 | CD46 | 225Ac | IgG1 | Prostate Cancer | Early stage | alpha (α) |
Ac-225-DOTATOC | Somatostatin receptors | 225Ac | Edotreotide | Neuroendocrine Tumor (NET) | Early stage | alpha (α) |
Ac-225-DOTAZOL | Bones | 225Ac | n/a | Bone pain palliation | Early stage | alpha (α) |
Ac-225-FPI-1434 | IGF-1R | 225Ac | FPI-1434 | Solid Tumors | In Clinical development | alpha (α) |
Ac-225-FPI-2059 | NTSR1 | 225Ac | 3BP-227 | Solid Tumors | Early stage | alpha (α) |
Ac-225-FPI-2068 | EGFR | 225Ac | Fab | Solid Tumors | Early stage | alpha (α) |
Ac-225-FPI-2265 | PSMA | 225Ac | PSMA-I&T | Prostate Cancer | In Clinical development | alpha (α) |
Ac-225-Lintuzumab (Ac-225 Actimab-A™) | CD33 | 225Ac | Lintuzumab | Acute Myeloid Leukemia (AML), Colon cancer | In Clinical development | alpha (α) |
Ac-225-MTI-201 | Melanocortin-1 | 225Ac | Fab | Uveal Cancer | Early stage | alpha (α) |
Publications
Interest in Theranostics grows as capabilities advance
By Richard Zimmermann, HealthCare Business, June 2020.
Radiotheranostics Momentum
By Richard Zimmermann, SNMMI Value Initiative, January 2021.
The Rising Role of Radiotheranostics Supported by the Oncidium Foundation
By Richard Zimmermann and Rebecca Lo bue, SNMMI Value Initiative, July 2021.
Actinium-225 Production and the Future. Needs for Labeled Drugs
By Richard Zimmermann, Radiotheranostics Today, March 2024.
Introduction to Phase 0 Imaging Studies with Radiopharmaceuticals
By Tracer CRO
Theranostics Insights
177Lu-FAP-2286
Therapy
211At-BC8-B10
Therapy
177Lu-DOTA-ROSOPATAMAB
Therapy
177Lu-DOTA-ABM-5G
Therapy
225Ac-DOTATATE
Therapy
188Rhenium-SCT
Therapy
177Lu-PSMA-IT
Therapy
177Lu-NeoB
Therapy
67Cu-SARTATE
Therapy
18F-FES
Imaging
64Cu-SAR-Bombesin
Imaging
177Lu-PSMA I&T
Therapy
177Lu-anti-PD-L1 sdAb
Therapy
177Lu-DPI-4452
Therapy
225Ac-FPI-1434
Therapy
188Re-RHN001
Therapy
177Lu-AKIR001
Therapy
177Lu-Girentuximab
Therapy